Hydrogel microsphere stem cell encapsulation enhances cardiomyocyte differentiation and functionality in scalable suspension system
Source abstract
Abstract
A reliable suspension-based platform for scaling engineered cardiac tissue (ECT) production from human induced pluripotent stem cells (hiPSCs) is crucial for regenerative therapies. Here, we compared the production and functionality of ECTs formed using our scaffold-based, engineered tissue microsphere differentiation approach with those formed using the prevalent scaffold-free aggregate platform. We utilized a microfluidic system for the rapid (1 million cells/min), high density (30, 40, 60 million cells/ml) encapsulation of hiPSCs within PEG-fibrinogen hydrogel microspheres. HiPSC-laden microspheres and aggregates underwent suspension-based cardiac differentiation in chemically defined media. In comparison to aggregates, microspheres maintained consistent size and shape initially, over time, and within and between batches. Initial size and shape coefficients of variation for microspheres were eight and three times lower, respectively, compared to aggregates. On day 10, microsphere cardiomyocyte (CM) content was 27 % higher and the number of CMs per initial hiPSC was 250 % higher than in aggregates. Contraction and relaxation velocities of microspheres were four and nine times higher than those of aggregates, respectively. Microsphere contractile functionality also improved with culture time, whereas aggregate functionality remained unchanged. Additionally, microspheres displayed improved β-adrenergic signaling responsiveness and uniform calcium transient propagation. Transcriptomic analysis revealed that while both microspheres and aggregates demonstrated similar gene regulation patterns associated with cardiomyocyte differentiation, heart development, cardiac muscle contraction, and sarcomere organization, the microspheres exhibited more pronounced transcriptional changes over time. Taken together, these results highlight the capability of the microsphere platform for scaling up biomanufacturing of ECTs in a suspension-based culture platform. • Comparison of scaffold-based and scaffold-free 3D hiPSC cardiac differentiation. • Microsphere provided tighter control of size and shape with higher reproducibility. • Microspheres showed higher cardiomyocyte (CM) content and more CMs/initial hiPSC. • Microsphere contracted faster than aggregate with higher cell structural maturity. • Microsphere platform exhibited more pronounced transcriptional changes over time.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · 3D Printing in Biomedical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (76)
Show source-provided references
1. Cardiac tissues from stem cells: new routes to maturation and cardiac regeneration10.1161/CIRCRESAHA.121.318183 ↗
2. Towards adult-like human engineered cardiac tissue: maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues10.1016/j.addr.2015.04.019 ↗
3. In situ expansion, differentiation, and electromechanical coupling of human cardiac muscle in a 3D bioprinted, chambered organoid10.1161/CIRCRESAHA.119.316155 ↗
4. Myocardial tissue engineering: in vitro models10.1101/cshperspect.a014076 ↗
5. Toward the realization of cardiac regenerative medicine using pluripotent stem cells10.1186/s41232-019-0110-4 ↗
6. Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells10.1016/j.scr.2015.08.002 ↗
7. Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells10.1186/scrt401 ↗
8. Naturally engineered maturation of cardiomyocytes10.3389/fcell.2017.00050 ↗
9. Current strategies and challenges for purification of cardiomyocytes derived from human pluripotent stem cells10.7150/thno.19427 ↗
10. A novel fluorescent reporter system identifies laminin-511/521 as potent regulators of cardiomyocyte maturation10.1038/s41598-020-61163-3 ↗
11. Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production10.1093/cvr/cvab115 ↗
12. 3D aggregate culture improves metabolic maturation of human pluripotent stem cell derived cardiomyocytes10.1002/bit.26504 ↗
13. Simple suspension culture system of human iPS cells maintaining their pluripotency for cardiac cell sheet engineering10.1002/term.1761 ↗
14. Large-scale production of human pluripotent stem cell derived cardiomyocytes10.1016/j.addr.2015.11.016 ↗
15. Scalable expansion of iPSC and their derivatives across multiple lineages10.1016/j.reprotox.2022.05.007 ↗
16. Development and characterization of a scaffold-free 3D spheroid model of induced pluripotent stem cell-derived human cardiomyocytes10.1089/ten.tec.2014.0376 ↗
17. Three-dimensional cell culture: the missing link in drug discovery10.1016/j.drudis.2012.10.003 ↗
18. Transcriptomic analysis of 3D cardiac differentiation of human induced pluripotent stem cells reveals faster cardiomyocyte maturation compared to 2D culture10.1038/s41598-019-45047-9 ↗
19. An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures10.1016/j.scr.2014.06.002 ↗
20. Selection of human induced pluripotent stem cells lines optimization of cardiomyocytes differentiation in an integrated suspension microcarrier bioreactor10.1186/s13287-020-01618-6 ↗
21. Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures10.1089/ten.tec.2010.0104 ↗
22. Electrically conductive chitosan/carbon scaffolds for cardiac tissue engineering10.1021/bm401679q ↗
23. Biomimetic scaffold combined with electrical stimulation and growth factor promotes tissue engineered cardiac development10.1016/j.yexcr.2013.11.005 ↗
24. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction10.1126/scitranslmed.3005503 ↗
25. Combining stem cells and biomaterial scaffolds for constructing tissues and cell delivery10.3233/STJ-180001 ↗
26. The synergy of scaffold-based and scaffold-free tissue engineering strategies10.1016/j.tibtech.2018.01.005 ↗
27. The multiparametric effects of hydrodynamic environments on stem cell culture10.1089/ten.teb.2011.0040 ↗
28. Engineering three-dimensional stem cell morphogenesis for the development of tissue models and scalable regenerative therapeutics10.1007/s10439-013-0953-9 ↗
29. Controlled self-assembly of stem cell aggregates instructs pluripotency and lineage bias10.1038/s41598-017-14325-9 ↗
30. Marked differences in differentiation propensity among human embryonic stem cell lines10.1038/nbt1383 ↗
31. Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture10.1016/j.stemcr.2014.09.017 ↗
32. Aggregate size optimization in microwells for suspension-based cardiac differentiation of human pluripotent stem cells10.3791/54308-v ↗
33. Production of homogenous size-controlled human induced pluripotent stem cell aggregates using ring-shaped culture vessel10.1002/term.3278 ↗
34. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor10.1002/bit.22065 ↗
35. Optimization of agitation speed in spinner flask for microcarrier structural integrity and expansion of induced pluripotent stem cells10.1007/s10616-014-9750-z ↗
36. In situ differentiation of human-induced pluripotent stem cells into functional cardiomyocytes on a coaxial PCL-gelatin nanofibrous scaffold10.1016/j.msec.2020.111354 ↗
37. Engineered cardiac tissue microsphere production through direct differentiation of hydrogel-encapsulated human pluripotent stem cells10.1016/j.biomaterials.2021.120818 ↗
38. Human induced pluripotent stem cell encapsulation geometry impacts three-dimensional developing human engineered cardiac tissue functionality10.1089/ten.tea.2022.0107 ↗
39. Emulsion-based encapsulation of pluripotent stem cells in hydrogel microspheres for cardiac differentiation10.1002/btpr.2986 ↗
40. Direct production of human cardiac tissues by pluripotent stem cell encapsulation in gelatin methacryloyl10.1021/acsbiomaterials.6b00226 ↗
41. Cardiac cell generation from encapsulated embryonic stem cells in static and scalable culture systems10.3727/096368910X513955 ↗
42. Rapid production of cell-laden microspheres using a flexible microfluidic encapsulation platform
43. Continuous WNT control enables advanced hPSC cardiac processing and prognostic surface marker identification in chemically defined suspension culture10.1016/j.stemcr.2019.06.004 ↗
44. Monitoring human-induced pluripotent stem cell-derived cardiomyocytes with genetically encoded calcium and voltage fluorescent reporters10.1016/j.stemcr.2015.08.009 ↗
45. Cardiac differentiation of human pluripotent stem cells in scalable suspension culture10.1038/nprot.2015.089 ↗
46. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration10.1016/j.biomaterials.2004.09.021 ↗
47. Morphological and compositional monitoring of a new cell-free cartilage repair hydrogel technology - GelrinC by MR using semi-quantitative MOCART scoring and quantitative T2 index and new zonal T2 index calculation10.1016/j.joca.2015.07.007 ↗
48. The effect of matrix stiffness of injectable hydrogels on the preservation of cardiac function after a heart attack10.1016/j.biomaterials.2013.10.058 ↗
49. Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures10.1016/j.biomaterials.2004.06.047 ↗
50. Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks
51. Chemically defined generation of human cardiomyocytes10.1038/nmeth.2999 ↗
52. High content analysis identifies unique morphological features of reprogrammed cardiomyocytes10.1038/s41598-018-19539-z ↗
53. SarcTrack an adaptable software tool for efficient large-scale analysis of sarcomere function in hiPSC-cardiomyocytes10.1161/CIRCRESAHA.118.314505 ↗
54. Characterization of mitochondrial populations during stem cell differentiation
55. Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stem cell-derived cardiomyocytes cultured over different spatial scales10.1089/ten.tec.2014.0283 ↗
56. Enhanced stem cell-derived cardiomyocyte differentiation in suspension culture by delivery of nitric oxide using S-nitrosocysteine10.1002/bit.25849 ↗
57. Integrating pharmacogenomics data-driven computational drug prediction with single-cell RNAseq to demonstrate the efficacy of a NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer10.3390/cancers14236009 ↗
58. Krämer · Causal analysis approaches in Ingenuity Pathway Analysis · 2014 · 30 · 523
59. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles10.1073/pnas.0506580102 ↗
60. Properties of embryoid bodies10.1002/wdev.259 ↗
61. Physiological and pathological cardiac hypertrophy10.1016/j.yjmcc.2016.06.001 ↗
62. A comprehensive analysis of gene expression changes in a high replicate and open-source dataset of differentiating hiPSC-derived cardiomyocytes10.1038/s41598-021-94732-1 ↗
63. Injectable polyethylene glycol-fibrinogen hydrogel adjuvant improves survival and differentiation of transplanted mesoangioblasts in acute and chronic skeletal-muscle degeneration10.1186/2044-5040-2-24 ↗
64. Direct hydrogel encapsulation of pluripotent stem cells enables ontomimetic differentiation and growth of engineered human heart tissues10.1016/j.biomaterials.2015.12.011 ↗
65. Using computational fluid dynamics (CFD) modeling to understand murine embryonic stem cell aggregate size and pluripotency distributions in stirred suspension bioreactors10.1016/j.jbiotec.2019.08.002 ↗
66. A 3D sphere culture system containing functional polymers for large-scale human pluripotent stem cell production10.1016/j.stemcr.2014.03.012 ↗
67. Bioreactor suspension culture: differentiation and production of cardiomyocyte spheroids from human induced pluripotent stem cells10.3389/fbioe.2021.674260 ↗
68. Characterization of 3D pluripotent stem cell aggregates and the impact of their properties on bioprocessing10.1016/j.procbio.2016.05.024 ↗
69. Forced aggregation and defined factors allow highly uniform-sized embryoid bodies and functional cardiomyocytes from human embryonic and induced pluripotent stem cells10.1007/s00380-013-0436-9 ↗
70. Role of cell-secreted extracellular matrix formation in aggregate formation and stability of human induced pluripotent stem cells in suspension culture10.1016/j.jbiosc.2018.08.010 ↗
71. A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells10.5966/sctm.2014-0275 ↗
72. Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine10.1038/s41569-019-0331-x ↗
73. Fabrication of 3D cardiac microtissue arrays using human iPSC-derived cardiomyocytes, cardiac fibroblasts, and endothelial cells10.3791/61879-v ↗
74. Generation and maturation of human iPSC-derived 3D organotypic cardiac microtissues in long-term culture10.1038/s41598-022-22225-w ↗
75. Deciphering role of Wnt signalling in cardiac mesoderm and cardiomyocyte differentiation from human iPSCs: four-dimensional control of Wnt pathway for hiPSC-CMs differentiation10.1038/s41598-019-55620-x ↗
76. The imprinted gene Delta like non-canonical Notch ligand 1 (Dlk1) is conserved in mammals, and serves a growth modulatory role during tissue development and regeneration through Notch dependent and independent mechanisms10.1016/j.cytogfr.2019.03.006 ↗